🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  2. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  3. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  4. GEN3014

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM)

    phase 2 mab terminated

    1 trial

  5. GEN3014 DP, DARZALEX 1800 mg solution for injection

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  6. GIOTRIF 40 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 20 mg film-coated tablets

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  7. GK1-399 (formerly TTP399)

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  8. GL0034 4 mg/ml, 1 ml per vial, GL0034 3 mg/ml, 1 ml per vial, Same solution as for GL0034 without drug substance; solution for subcutaneous injection; volume identical to dose of test product, GL0034 1mg/ml, 0.6ml per vial, GL0034 1 mg/ml, 1 ml per vial

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  9. GSK221149A

    GlaxoSmithKline

    Obstetric Labour, Premature

    phase 2 small molecule completed

    1 trial

  10. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  11. GWP42004

    Jazz Pharmaceuticals Ireland Limited

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  12. GZR102

    Gan & Lee Pharmaceuticals.

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule active

    1 trial

  13. Gabapentin

    Lxo Ireland Designated Activity Company

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  14. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Benzodiazepine Dependence

    phase 2 small molecule completed

    1 trial

  15. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 small molecule active

    1 trial

  16. Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    Astra Zeneca AB

    Recipients of allogeneic stem cell transplantation

    phase 2 small molecule active

    1 trial

  17. Gazyvaro 1,000 mg concentrate for solution for infusion.

    Pari Pharma GmbH

    Non-infectious active cryoglobulinemia vasculitis who are either refractory or intolerant to Rituximab

    phase 2 small molecule active

    1 trial

  18. Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  19. Gazyvaro 1,000 mg concentrate for solution for infusion., Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, Zanubrutinib, Mosunetuzumab, Columvi 10 mg concentrate for solution for infusion, Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11417, BGB-16673, Gazyvaro 1,000 mg concentrate for solution for infusion., BGB-11

    BEONE MEDICINES AUS PTY LTD

    Relapsed or Refractory B-Cell Malignancies

    phase 2 small molecule active

    1 trial

  20. Gazyvaro 1,000 mg concentrate for solution for infusion., OMNIPAQUE 300 mg I/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Idiopathic Nephrotic Syndrome

    phase 2 small molecule active

    1 trial

  21. Gemcitabine

    Compass Therapeutics

    Metastatic Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  22. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  23. Gemcitabine

    Arcus Biosciences

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  24. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources